Document Type
Article
Journal/Book Title
BMC Neuroscience
Publication Date
11-30-2009
Publisher
BioMed Central
Volume
10
Issue
142
Abstract
Background Spinal Muscular Atrophy (SMA) is the leading genetic cause of infantile death. It is caused by the loss of functional Survival Motor Neuron 1 (SMN1). There is a nearly identical copy gene, SMN2, but it is unable to rescue from disease due to an alternative splicing event that excises a necessary exon (exon 7) from the majority of SMN2-derived transcripts. While SMNΔ7 protein has severely reduced functionality, the exon 7 sequences may not be specifically required for all activities. Therefore, aminoglycoside antibiotics previously shown to suppress stop codon recognition and promote translation read-through have been examined to increase the length of the SMNΔ7 C-terminus. Results Here we demonstrate that subcutaneous-administration of a read-through inducing compound (TC007) to an intermediate SMA model (Smn-/-; SMN2+/+; SMNΔ7) had beneficial effects on muscle fiber size and gross motor function. Conclusion Delivery of the read-through inducing compound TC007 reduces the disease-associated phenotype in SMA mice, however, does not significantly extend survival.
Recommended Citation
Mattis, V. B.; Fosso, M. Y.; Chang, C.-W. T.; Lorson, C. L. “Subcutaneous administration of TC007 reduces disease severity in an animal model of SMA.” BMC Neurosci. 2009, 10, 142. PubMed PMID: 19948047; PubMed Central PMCID: PMC2789732.
Comments
PubMed PMID: 19948047; PubMed Central PMCID: PMC2789732